H.C. Wainwright analyst Swayampakul Ramakanth lowered the firm’s price target on ALX Oncology to $65 from $80 and keeps a Buy rating on the shares post the Q3 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALXO: